Fennec Pharmaceuticals Inc. (FRX.TO)
CAD 8.12
(-6.34%)
CAD 8.12
(-6.34%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -12.36 Million USD | 45.3% |
| 2022 | -22.58 Million USD | -31.18% |
| 2021 | -17.18 Million USD | 4.45% |
| 2020 | -17.98 Million USD | -38.25% |
| 2019 | -13 Million USD | -23.0% |
| 2018 | -10.57 Million USD | -55.14% |
| 2017 | -6.81 Million USD | -130.38% |
| 2016 | -2.95 Million USD | 5.1% |
| 2015 | -3.11 Million USD | 12.81% |
| 2014 | -3.57 Million USD | -85.09% |
| 2013 | -1.93 Million USD | 46.33% |
| 2012 | -3.6 Million USD | -6.04% |
| 2011 | -3.39 Million USD | -150.92% |
| 2010 | -1.35 Million USD | 47.98% |
| 2009 | -2.6 Million USD | 81.05% |
| 2008 | -13.72 Million USD | 1.97% |
| 2007 | -13.99 Million USD | 4.22% |
| 2006 | -14.61 Million USD | 2.12% |
| 2005 | -14.93 Million USD | 0.0% |
| 2003 | -6.9 Million USD | -32.29% |
| 2002 | -5.21 Million USD | -23.12% |
| 2001 | -4.23 Million USD | -52.04% |
| 2000 | -2.59 Million USD | -78.48% |
| 1999 | -1.55 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -4.46 Million USD | -130.99% |
| 2024 Q1 | 14.64 Million USD | 952.45% |
| 2023 Q3 | -915 Thousand USD | 79.89% |
| 2023 Q1 | -5.16 Million USD | 14.72% |
| 2023 Q2 | -4.55 Million USD | 11.82% |
| 2023 Q4 | -1.7 Million USD | -86.12% |
| 2023 FY | - USD | 45.3% |
| 2022 Q4 | -6.05 Million USD | 23.77% |
| 2022 Q1 | -3.54 Million USD | 15.48% |
| 2022 FY | - USD | -31.18% |
| 2022 Q3 | -7.93 Million USD | -58.53% |
| 2022 Q2 | -5 Million USD | -41.31% |
| 2021 Q2 | -3.9 Million USD | 23.45% |
| 2021 Q3 | -4.16 Million USD | -6.68% |
| 2021 Q4 | -4.19 Million USD | -0.58% |
| 2021 FY | - USD | 4.45% |
| 2021 Q1 | -5.1 Million USD | -52.57% |
| 2020 Q3 | -5.85 Million USD | -20.93% |
| 2020 Q1 | -3.83 Million USD | -4.98% |
| 2020 Q4 | -3.34 Million USD | 42.89% |
| 2020 FY | - USD | -38.25% |
| 2020 Q2 | -4.84 Million USD | -26.34% |
| 2019 Q1 | -2.61 Million USD | 15.81% |
| 2019 Q3 | -1.86 Million USD | 60.47% |
| 2019 Q2 | -4.71 Million USD | -80.3% |
| 2019 FY | - USD | -23.0% |
| 2019 Q4 | -3.65 Million USD | -96.08% |
| 2018 Q2 | -2.66 Million USD | -36.11% |
| 2018 Q3 | -2.84 Million USD | -6.87% |
| 2018 Q4 | -3.1 Million USD | -9.02% |
| 2018 Q1 | -1.95 Million USD | 28.04% |
| 2018 FY | - USD | -55.14% |
| 2017 FY | - USD | -130.38% |
| 2017 Q2 | -1.35 Million USD | -85.15% |
| 2017 Q4 | -2.72 Million USD | -35.85% |
| 2017 Q3 | -2 Million USD | -47.39% |
| 2017 Q1 | -734 Thousand USD | 36.12% |
| 2016 Q4 | -1.14 Million USD | -84.43% |
| 2016 FY | - USD | 5.1% |
| 2016 Q1 | -488 Thousand USD | 11.75% |
| 2016 Q3 | -623 Thousand USD | 9.71% |
| 2016 Q2 | -690 Thousand USD | -41.39% |
| 2015 Q1 | -1.07 Million USD | 27.62% |
| 2015 Q3 | -554 Thousand USD | 40.69% |
| 2015 Q4 | -553 Thousand USD | 0.18% |
| 2015 Q2 | -934 Thousand USD | 13.28% |
| 2015 FY | - USD | 12.81% |
| 2014 Q1 | 2.11 Million USD | 614.08% |
| 2014 Q4 | -1.48 Million USD | -140.78% |
| 2014 Q2 | -1.11 Million USD | -152.46% |
| 2014 Q3 | -618 Thousand USD | 44.37% |
| 2014 FY | - USD | -85.09% |
| 2013 Q3 | -51 Thousand USD | 94.49% |
| 2013 Q4 | -412 Thousand USD | -707.84% |
| 2013 FY | - USD | 46.33% |
| 2013 Q2 | -925 Thousand USD | -72.9% |
| 2013 Q1 | -535 Thousand USD | -119.6% |
| 2012 Q1 | -3.93 Million USD | -239.48% |
| 2012 Q3 | -491 Thousand USD | 74.09% |
| 2012 Q4 | 2.72 Million USD | 655.8% |
| 2012 FY | - USD | -6.04% |
| 2012 Q2 | -1.89 Million USD | 51.89% |
| 2011 FY | - USD | -150.92% |
| 2011 Q4 | 2.82 Million USD | 121.14% |
| 2011 Q3 | 1.27 Million USD | 323.25% |
| 2011 Q2 | -572 Thousand USD | 43.42% |
| 2011 Q1 | -1.01 Million USD | -120.37% |
| 2010 Q1 | -366 Thousand USD | -157.28% |
| 2010 FY | - USD | 47.98% |
| 2010 Q4 | 4.96 Million USD | 241.17% |
| 2010 Q3 | -3.51 Million USD | -795148.87% |
| 2010 Q2 | -442.00 USD | 99.88% |
| 2009 FY | - USD | 81.05% |
| 2009 Q4 | 639 Thousand USD | 199.07% |
| 2009 Q3 | -645 Thousand USD | 34.38% |
| 2009 Q2 | -983 Thousand USD | 39.02% |
| 2009 Q1 | -1.61 Million USD | 38.38% |
| 2008 Q2 | -3.46 Million USD | 20.66% |
| 2008 Q1 | -4.36 Million USD | -38.05% |
| 2008 FY | - USD | 1.97% |
| 2008 Q4 | -2.61 Million USD | 20.37% |
| 2008 Q3 | -3.28 Million USD | 5.06% |
| 2007 FY | - USD | 4.22% |
| 2007 Q4 | -3.15 Million USD | 7.09% |
| 2007 Q1 | -4.05 Million USD | 14.96% |
| 2007 Q2 | -3.38 Million USD | 16.68% |
| 2007 Q3 | -3.4 Million USD | -0.56% |
| 2006 Q4 | -4.77 Million USD | -1.6% |
| 2006 FY | - USD | 2.12% |
| 2006 Q3 | -4.69 Million USD | -19.85% |
| 2006 Q2 | -3.91 Million USD | -20.69% |
| 2006 Q1 | -3.24 Million USD | 57.31% |
| 2005 Q3 | -4.03 Million USD | 3.64% |
| 2005 Q2 | -4.18 Million USD | -58.01% |
| 2005 Q1 | -2.64 Million USD | 0.0% |
| 2005 Q4 | -7.6 Million USD | -88.63% |
| 2005 FY | - USD | 0.0% |
| 2004 Q1 | -2.12 Million USD | -40.88% |
| 2004 Q3 | -2.51 Million USD | -8.59% |
| 2004 Q2 | -2.31 Million USD | -9.15% |
| 2003 Q2 | -1.6 Million USD | -23.36% |
| 2003 FY | - USD | -32.29% |
| 2003 Q4 | -1.5 Million USD | -45.03% |
| 2003 Q3 | -1.03 Million USD | 35.76% |
| 2003 Q1 | -1.3 Million USD | -37.61% |
| 2002 Q3 | -1.12 Million USD | 23.13% |
| 2002 Q2 | -1.44 Million USD | -65.55% |
| 2002 Q1 | -879.04 Thousand USD | -9.61% |
| 2002 FY | - USD | -23.12% |
| 2002 Q4 | -929.82 Thousand USD | 17.21% |
| 2001 Q2 | -2.64 Million USD | -417585523.13% |
| 2001 FY | - USD | -52.04% |
| 2001 Q4 | -668.69 Thousand USD | 18.92% |
| 2001 Q3 | -929.52 Thousand USD | 61.54% |
| 2001 Q1 | 0.63 USD | 100.0% |
| 2000 FY | - USD | -78.48% |
| 2000 Q3 | 0.67 USD | 0.0% |
| 2000 Q4 | -539.7 Thousand USD | -85971174.16% |
| 1999 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Appili Therapeutics Inc. | -2.09 Million CAD | -489.779% |
| Eupraxia Pharmaceuticals Inc. | -37.39 Million CAD | 66.937% |
| Helix BioPharma Corp. | -9.38 Million CAD | -31.686% |
| Microbix Biosystems Inc. | 1.95 Million CAD | 731.763% |
| Medicenna Therapeutics Corp. | -18.67 Million CAD | 33.776% |
| Satellos Bioscience Inc. | -15.7 Million CAD | 21.273% |
| Oncolytics Biotech Inc. | -33.71 Million CAD | 63.322% |
| Sernova Corp. | -40.19 Million CAD | 69.239% |